Marshall Wace LLP Makes New $4.78 Million Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Marshall Wace LLP purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 290,734 shares of the company’s stock, valued at approximately $4,780,000. Marshall Wace LLP owned about 0.54% of Upstream Bio as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. US Bancorp DE bought a new position in Upstream Bio during the 4th quarter worth approximately $27,000. Legal & General Group Plc acquired a new stake in shares of Upstream Bio during the fourth quarter worth $28,000. Summit Investment Advisors Inc. bought a new position in Upstream Bio during the fourth quarter worth $30,000. Corebridge Financial Inc. acquired a new position in Upstream Bio in the fourth quarter valued at $142,000. Finally, Wells Fargo & Company MN bought a new stake in Upstream Bio during the fourth quarter valued at $149,000.

Upstream Bio Trading Up 1.7 %

Shares of Upstream Bio stock opened at $8.96 on Friday. The business has a 50-day moving average price of $7.87 and a two-hundred day moving average price of $14.49. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.